|
Post by yossarian on May 11, 2015 9:12:11 GMT -5
Three say buy, three say hold, and three say sell. You pays your money and takes your changes.
BUZZ-MannKind Corp: JP Morgan downgrades; MLV cuts price target 9:51 AM ET, 05/11/2015 - Reuters
** Drugmaker's shares down 7 pct at $3.54 premarket
** J.P. Morgan Securities analysts downgrade stock to "underweight" from "neutral"; MLV Partners analysts cut price target to $4 from $7, citing lower-than-expected Q1 sales of its inhaled insulin Afrezza
** Median price target on stock is $4
** Of nine brokerages covering stock, three have a "buy" or higher ratings, three "hold" and three "sell"
** Up to Friday's close, stock had fallen 27 pct this year
|
|
|
Post by maytepper on May 11, 2015 19:06:36 GMT -5
|
|
|
Post by joeypotsandpans on May 11, 2015 19:18:38 GMT -5
www.tipranks.com/experts/cory-kasimov?ref=sa-experthit the link above and then hit the green MNKD bar, when you look at the graph he put out holds 3 separate times since the high of last year when it was $10+ and now at the low's in the mid $3's he puts a sell....curious to what you think that says to you May?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 11, 2015 19:30:39 GMT -5
One quote in here "Kasimov commented: “Afrezza’s launch has been predictably slow out of the gate (1Q sales of ~$1.1M, incl stocking)." I don't recall finding the "including stocking" myself. However, now it's being reported that the 1.1 mil includes product stocking? Can someone confirm that this is what sano said, because I was looking for it/paying attention on this detail but I don't recall hearing that from sano. Can anyone confirm? If it in fact includes product stocking, then that throws out trying to use the 1 mil rev number to adjust script counts. We can't confirm higher scripts if that 1.1 million includes stocking product.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 11, 2015 19:32:00 GMT -5
You can't confirm that anyway because of rounding. MNKDs $7mil includes stocking and samples, SNYs sales are sales.
|
|
|
Post by EveningOfTheDay on May 12, 2015 2:48:19 GMT -5
|
|
|
Post by liane on May 12, 2015 4:52:08 GMT -5
Thanks eod!
I also put the link in our Griffin thread in the "Resource Center"
|
|
|
Post by eddiemoy on May 12, 2015 6:16:01 GMT -5
|
|
|
Post by kball on May 12, 2015 6:44:27 GMT -5
The thing that stood out to me from Griffin... Griffin Securities has received compensation from MannKind Corp. in the past 12 months for non- investment banking services.But also this was a shocker... Indeed, Sanofi announced last fall that it would advise physicians to prescribe Afrezza initially to patients whose glucose levels were well controlled and that suggested patient selection would slow adoption of the drug.
Well controlled? wtf?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2015 8:55:34 GMT -5
Thanks for the information.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2015 8:57:51 GMT -5
The thing that stood out to me from Griffin... Griffin Securities has received compensation from MannKind Corp. in the past 12 months for non- investment banking services.But also this was a shocker... Indeed, Sanofi announced last fall that it would advise physicians to prescribe Afrezza initially to patients whose glucose levels were well controlled and that suggested patient selection would slow adoption of the drug.
Well controlled? wtf? Would not be thrilled about SNY picking patients whose BG are well controlled but you also need to consider the results Sam has been getting and Brian Sharp who just posted his A1C at 5.7 vs I believe 10.1 at the start. Not enough data points yet on either side to extrapolate to the masses but all we have now is limited data so it is what it is. This all should get interesting come August. Then we start to see the real tale of the tape.
|
|
|
Post by petech on May 12, 2015 9:20:34 GMT -5
The thing that stood out to me from Griffin... Griffin Securities has received compensation from MannKind Corp. in the past 12 months for non- investment banking services.But also this was a shocker... Indeed, Sanofi announced last fall that it would advise physicians to prescribe Afrezza initially to patients whose glucose levels were well controlled and that suggested patient selection would slow adoption of the drug.
Well controlled? wtf? As to the first comment...no idea what that's about. That said, unless they are being paid to provide this report (which they aren't), I wouldn't worry about the attenuated conflict of interest alluded to. As to the second comment, I was at first annoyed. Then I thought...we're trying to instill a sea change here...not just a new insulin to put into your syringe. So...if we're going to do that, we need to show how well this works in the real world. Who better to adopt than people who are well controlled...and therefore on top of the learning curve on diabetes medicine? Also, as these people are "well controlled"...won't that allow a previous baseline to compare the "Afrezza Affect" against? Yeah....this makes sense....that's who I would target if I were doing this. Sure we can do the uncontrolled people....but they're going to have a bunch of issues otherwise and it would be much more difficult to quantify improvement. Plus...uncontrolled = not good about taking medicine to begin with...so they're not the front-line people we'd like to use. I'm starting to feel good again. August is the 6 month anniversary of when insurance issues hopefully start to get better...plus DTC happens....plus (according to Matt) the debt is either paid off or refinanced; either way without a dilutive secondary. Plus, we should have actual A1C numbers from first adopters to start throwing around....which based on very limited accounts from social media...are very good. So I'm thinking sales start going nuts in the August/September time frame (i.e., we start seeing the uptrend we're all anticipating). Problem is...there is a lot of time between then and now....and absent a partnership on technosphere...it will be a lot easier for shorts to scream about this stock than it will be for the longs to scream about it. So be ready for that. And if you are a lunatic such as myself...use the weakness to your advantage to add to your position
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 12, 2015 9:24:14 GMT -5
The thing that stood out to me from Griffin... Griffin Securities has received compensation from MannKind Corp. in the past 12 months for non- investment banking services.But also this was a shocker... Indeed, Sanofi announced last fall that it would advise physicians to prescribe Afrezza initially to patients whose glucose levels were well controlled and that suggested patient selection would slow adoption of the drug.
Well controlled? wtf? As to the first comment...no idea what that's about. That said, unless they are being paid to provide this report (which they aren't), I wouldn't worry about the attenuated conflict of interest alluded to. As to the second comment, I was at first annoyed. Then I thought...we're trying to instill a sea change here...not just a new insulin to put into your syringe. So...if we're going to do that, we need to show how well this works in the real world. Who better to adopt than people who are well controlled...and therefore on top of the learning curve on diabetes medicine? Also, as these people are "well controlled"...won't that allow a previous baseline to compare the "Afrezza Affect" against? Yeah....this makes sense....that's who I would target if I were doing this. Sure we can do the uncontrolled people....but they're going to have a bunch of issues otherwise and it would be much more difficult to quantify improvement. Plus...uncontrolled = not good about taking medicine to begin with...so they're not the front-line people we'd like to use. I'm starting to feel good again. August is the 6 month anniversary of when insurance issues hopefully start to get better...plus DTC happens....plus (according to Matt) the debt is either paid off or refinanced; either way without a dilutive secondary. Plus, we should have actual A1C numbers from first adopters to start throwing around....which based on very limited accounts from social media...are very good. So I'm thinking sales start going nuts in the August/September time frame (i.e., we start seeing the uptrend we're all anticipating). Problem is...there is a lot of time between then and now....and absent a partnership on technosphere...it will be a lot easier for shorts to scream about this stock than it will be for the longs to scream about it. So be ready for that. And if you are a lunatic such as myself...use the weakness to your advantage to add to your position :) You make a great point. If a group of patients is well controlled and achieves even better control and further reduced incidences of hypos on Afrezza and this all shows statistically significant improvement for the patient along with further reductions in long term health complications due to incremental improvement in control of hypos and reduced blood glucose levels then Afrezza becomes even more valuable.
|
|
|
Post by petech on May 12, 2015 14:11:47 GMT -5
Thank you. I was rather proud of the musings I was able to produce wearing my tin foil hat.
|
|
|
Post by mnholdem on May 12, 2015 14:54:17 GMT -5
As to the first comment...no idea what that's about. That said, unless they are being paid to provide this report (which they aren't), I wouldn't worry about the attenuated conflict of interest alluded to. As to the second comment, I was at first annoyed. Then I thought...we're trying to instill a sea change here...not just a new insulin to put into your syringe. So...if we're going to do that, we need to show how well this works in the real world. Who better to adopt than people who are well controlled...and therefore on top of the learning curve on diabetes medicine? Also, as these people are "well controlled"...won't that allow a previous baseline to compare the "Afrezza Affect" against? Yeah....this makes sense....that's who I would target if I were doing this. Sure we can do the uncontrolled people....but they're going to have a bunch of issues otherwise and it would be much more difficult to quantify improvement. Plus...uncontrolled = not good about taking medicine to begin with...so they're not the front-line people we'd like to use. I'm starting to feel good again. August is the 6 month anniversary of when insurance issues hopefully start to get better...plus DTC happens....plus (according to Matt) the debt is either paid off or refinanced; either way without a dilutive secondary. Plus, we should have actual A1C numbers from first adopters to start throwing around....which based on very limited accounts from social media...are very good. So I'm thinking sales start going nuts in the August/September time frame (i.e., we start seeing the uptrend we're all anticipating). Problem is...there is a lot of time between then and now....and absent a partnership on technosphere...it will be a lot easier for shorts to scream about this stock than it will be for the longs to scream about it. So be ready for that. And if you are a lunatic such as myself...use the weakness to your advantage to add to your position You make a great point. If a group of patients is well controlled and achieves even better control and further reduced incidences of hypos on Afrezza and this all shows statistically significant improvement for the patient along with further reductions in long term health complications due to incremental improvement in control of hypos and reduced blood glucose levels then Afrezza becomes even more valuable.
I occurs to me that Sanofi may have been concerned with the negative publicity that may be generated if insulin-naïve T-2 diabetics started over-dosing themselves using Afrezza. I'm guessing that they initially want Afrezza in the hands of the Sam's, Eric's and Amy's - all Type 1's - not to mention FIRST-TIME INSULIN USERS like spiro.
I share the concern that another member of this forum recently posted that our competitors may be eager publicize problems with Afrezza. I don't know if other BPs go to the extreme of paying a "marker" to intentionally put themselves in the hospital or not.
This strategy may have been to prevent accidents and bad publicity until sufficient dosing information is gathered for the benefit of diabetics and physicians. Don't forget that the trials were very controlled. Not any more. Diabetics can - and will - choose to use Afrezza for various needs in in various ways.
Initial reports indicate that Afrezza simplifies controlling blood glucose, but there is still a great deal to learn and diabetes is nothing to play around with.
|
|